Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

GlaxoSmithKline Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (226)
ARTG (117)
Australian Public Assessment Report (AusPAR) (40)
Prescription medicine registration (17)
Designation or determination (5)
Prescription medicine decision summary (3)
Prescription medicine evaluation (3)
Face mask cancellation (1)

Date

2024 (10)
2023 (18)
2022 (62)
2021 (12)
2020 (60)
2019 (31)
2018 (27)
2017 (24)
2016 (11)
2015 (51)
2014 (24)
2013 (9)
2012 (6)
2011 (4)
2010 (7)
2009 (3)
2008 (6)
2007 (6)
2006 (3)
2005 (4)
2004 (1)
2003 (3)
2002 (3)
2001 (1)
2000 (3)
1999 (4)
1998 (5)
1997 (4)
1995 (1)
1992 (2)
1991 (6)

Results for "[search-keyword]"

Search

Sponsor content

412 result(s) found, displaying 111 to 120

ZEJULA niraparib (as tosilate monohydrate) 100 mg capsule blister pack (305254)

28 June 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for ZEJULA niraparib (as tosilate monohydrate) 100 mg capsule blister pack.
GlaxoSmithKline Australia Pty Ltd - Inhaler, aerosol, portable (315987)

1 April 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for GlaxoSmithKline Australia Pty Ltd - Inhaler, aerosol, portable.
ARNUITY ELLIPTA fluticasone furoate 50 microgram powder for inhalation dry powder inhaler (300141)

14 March 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for ARNUITY ELLIPTA fluticasone furoate 50 microgram powder for inhalation dry powder inhaler.
BECODERM-C FLARE-UP ECZEMA AND DERMATITIS CREAM clobetasone butyrate 0.5mg/g tube Cancelled under Section 30(1)(c) of the Act

14 December 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
GlaxoSmithKline Australia Pty Ltd - Spoon, medicine, reusable Cancelled under Section 41GL(d) of the Act

14 December 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
GlaxoSmithKline Australia Pty Ltd - Dispenser, medication, liquid Cancelled under Section 41GL(d) of the Act

14 December 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
FLOLAN epoprostenol sodium 500 microgram powder for injection vial Cancelled under Section 30(1)(c) of the Act

14 December 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
FLOLAN epoprostenol sodium 1.5 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

14 December 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
GlaxoSmithKline Australia Pty Ltd - Mask Cancelled under Section 41GL(d) of the Act

20 November 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
Zofran Injection Solution Ampoules 4mg/2mL Cancelled under Section 30(1)(c) of the Act

4 November 2020

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd

Pages

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Current page 12
Page 13
Page 14
Page 15
Page 16
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.